THBS4 and neoplasm: THBS4 promoter hypermethylation (PMR ≥10) was observed in 4/30 (13.3%) CIMP-NEG tumours, 4/11 (36.4%) CIMP-L tumours, and 5/14 (35.7%) CIMP-H tumours.